SCHEMBL2290902

SCHEMBL2290902

C=CC[Si](O)(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.36
TSHR P16473 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
MMP9 P14780 1/20 0.35
MAOB P27338 1/20 0.34
NR1H2 P55055 2/20 0.34
NR1H3 Q13133 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
TDP1 Q9NUW8 2/20 0.33
APOBEC3G Q9HC16 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CALM1 P0DP23 1/20 0.33
ALDH1A1 P00352 1/20 0.32
THRB P10828 1/20 0.32
IDO1 P14902 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15302578 0.96 GAA (0.36) GAATSHRL3MBTL1MMP9MAOB
SCHEMBL2287214 0.89 TP53 (0.35) GAATSHRL3MBTL1MMP9MAOB
SCHEMBL2286929 0.86 GAA (0.37) GAAL3MBTL1MMP9NR1H2NR1H3
SCHEMBL8762346 0.83 CES2 (0.37) GAATSHRL3MBTL1MMP9MAOB
SCHEMBL2286987 0.83 EPHX2 (0.35) GAASMN1; SMN2THRB
SCHEMBL2286891 0.80 NR1H2 (0.39) GAATSHRL3MBTL1MMP9MAOB
SCHEMBL379345 0.79 TSHR (0.48) TSHRMAOBNR1H2NR1H3TDP1
SCHEMBL15302531 0.79 MMP9 (0.38) GAATSHRMMP9MAOBNR1H2
SCHEMBL2292298 0.79 NR1H2 (0.35) GAATSHRMMP9MAOBNR1H2
SCHEMBL14472080 0.78 MAOB (0.37) GAATSHRL3MBTL1MMP9MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268489-B2 Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery comprising the same LG CHEM, LTD. (KR) 2012-09-18 US claimed
US-20110206999-A1 NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME LG CHEM, LTD. (KR) 2011-08-25 US claimed
US-8791221-B2 Addition-curable metallosiloxane compound DAICEL CORPORATION (JP) 2014-07-29 US disclosed
EP-2650319-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND Daicel Corporation (JP) 2013-10-16 EP disclosed
US-20130267653-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND DAICEL CORPORATION (JP) 2013-10-10 US disclosed
US-8268489-B2 Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery comprising the same LG CHEM, LTD. (KR) 2012-09-18 US disclosed
US-20110206999-A1 NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME LG CHEM, LTD. (KR) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267653-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND B2M, MSI2, MNS1 GAA 3073/4885TSHR 4702/4885L3MBTL1 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.